DCI Research

Survey of 360 parents, caregivers of pediatric cancer patients, led by Kyle Walsh, PhD, found canceled/delayed appointments, increased anxiety, financial distress.

A research team led by Andrew Armstrong, MD, MSc, identifies new targets for treating non-clear cell renal carcinoma.

DCI, with 130 cancer centers & orgs, signed letter urging Biden admin. & U.S. states to continue prioritizing cancer patients, survivors in COVID-19 vaccine rollout.

Nobel laureate and DCI member Robert Lefkowitz’ first memoir, “A Funny Thing Happened on the Way to Stockholm,” was published this month.

Susan Dent, MD, co-director of the Duke Cardio-Oncology Program, is a leading international expert in the field. She is also associate director of Clinical Research in DCI's Breast Program.

Qualifying patients get access to blood draws at home or at a nearby lab and the services of a nurse coach for symptom management & emotional support.

DCI director Michael B. Kastan, MD, PhD, announced a planned reconfiguration of DCI’s NCI-Designated Research Programs and welcomed new research leaders.

DCI members Afreen Idris Shariff, MD, & Tian Zhang, MD, have launched a podcast on immune-related toxicities.

The finding from a genetic analysis of tumors treated with Duke’s poliovirus therapy suggests a predictive biomarker for survival.

Joab Odera, PhD, a postdoctoral researcher in DCI's Patierno/Freedman/George Lab is among 13 Duke scientists named to list of 1,000 inspiring Black scientists.

Susan Halabi, PhD, is co-leading a project to create a large international registry of data from prostate cancer patients treated with various PARP inhibitors.

Finding the Answers, Together

Charles A. Gersbach, PhD (CRISPR technologies) and a Microsoft research industry executive (research in the cloud) are among the speakers.

Ken Young, MD, PhD, will assume the role of chief, Hematopathology Division and DCI Blood Cancer Pathology Service, on Jan. 1, 2021.

A study co-led at Duke SoM & Mass. General Hospital demonstrates benefits of early palliative care for high-risk leukemia patients. Results published in JAMA. Thomas LeBlanc, MD, is co-lead author.

A Duke research team has identified a molecular process by which lung cancer cells metastasize to the brain.

DCI pathologist Jung Wook Park, PhD, mentored by Jiaoti Huang, MD, PhD, and Andrew Armstrong, MD, MSc, has received a Prostate Cancer Foundation Young Investigator Award.

A decade since it’s discovery in the Patz Lab, a first-in-class, novel targeted immunotherapy developed at DCI, is now in a phase 1b clinical trial.

The NAI recognizes academic inventors for their spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and welfare of society. 

Urologist Judd Moul, MD, presented and answered questions at “A No-nonsense Interactive discussion on Active Surveillance and Prostate Cancer."

You can count on one hand the number of times a young graduate student finds a drug, then the drug is patented, licensed, and in a phase 2 trial within a couple years.

Who should get screened and what happens if something is found ?

Siqi Li was one of six senior PhD students in the School of Medicine were awarded the Chancellor’s Award for Research Excellence in basic science research. 

Brent Hanks, MD, PhD, was named associate director of Translational Science for the Melanoma Disease Group this month.

Angelo Moore, PhD, MSN, RN, NE-BC, retired from the Army in 2015, but his service to his countrymen continues. In civilian life, he serves the historically underserved.

An injectable drug used to reduce stubbornly high cholesterol levels appears in animal studies to also enhance the immune response of immune checkpoint inhibitors.

The American Cancer Society has a long history of awarding grants to DCI researchers as they work to better understand the complexities of cancer and develop new treatments.

Daniel Sullivan, MD, professor emeritus in the Duke University Department of Radiology, received an award from the Prevent Cancer Foundation, on Oct. 28.

SHIELD-RT is, broadly across medicine, “one of the first randomized interventional studies to see if machine learning can improve patient outcomes."

NCI welcomes the Duke BioRepository & Precision Pathology Center as the new site of the Southern Division of the Cooperative Human Tissue Network.

Researchers in the Netherlands reported last week on their discovery of a set of previously unidentified head & neck organs. Yvonne Mowery, MD, PhD, weighs in.

One top trainee from each of the eight DCI Research Programs presented their pioneering cancer research projects. Benjamin Mayro received the Bell Award.

Komen scholar Donald McDonnell, PhD, spoke about the importance of investing in breast cancer research at MBC gala that raised $150K.

Katrina Cooke has beaten the odds; surviving nearly nine years with metastatic breast cancer. Giving of her time to make things better for others has been her lifeline.

DCI faculty Michaela Dinan, PhD, on the impact of the Oncotype DX test on HR+ breast cancer patients over 65, treatment disparities, & the latest therapies.

Donald McDonnell, PhD, has been recognized for his leadership in estrogen receptor biology by Susan G. Komen with a Brinker Award for Scientific Distinction in Basic Science.
 

Gynecologic oncologist Angeles Alvarez Secord, MD, MHS, weighs in on screening & symptoms in ovarian cancer. September is National Ovarian Cancer Awareness Month.

Komen NCTC hosts its first annual gala to support metastatic breast cancer research; a virtual event with speakers, auctions, and treats on Saturday, October 10, at 7 p.m.

A new approach to training computational models on biological processes provides insights into how and why cancer cells metastasize to certain areas of the vasculature.

Diagnosed with stage 4 ovarian cancer three years ago, Kathy Jennings was thrown a lifeline when she came to Duke Cancer Center.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

Radiation oncologist Joseph Kamel Salama, MD, named to the 2020 class of ASTRO Fellows.

New optical sensing platform can detect genomic cancer biomarkers directly in patient tissues.

Research led by DCI member David Sherwood, PhD, may help pinpoint what might be going wrong in human diseases ranging from kidney disease to invasive cancer.

On-demand viewing of AACR Annual Meeting sessions is now available. Duke presenters included Hema Adhikari, PhD, and Daniel George, MD.

Duke Cancer Institute welcomes a new clinical investigator specializing in bladder cancer to its Genitourinary Oncology program.

In May, a phased-in process of reopening labs began, and by June 15 most labs were functioning at least on a partial basis.

On June 9, DCI and Susan G. Komen Triangle to Coast hosted "Navigating Survivorship,"a live patient forum on breast cancer and survivorship.

Cancer doesn't wait for COVID-19.

The Donald Lab, led by Bruce Donald, PhD, is designing proteins for a historically undruggable protein that’s implicated in difficult-to-treat cancers like pancreatic cancer.